A Malaria Antibody Cut Infant Infections by 78%. It Also Weakened Their Vaccine.
The NIAID antibody L9LS cut infant malaria infections by 78% in Mali and weakened the response to the R21 vaccine, and the planned interaction study has been withdrawn. Inside the immunology that now shapes how malaria tools get sequenced.












